These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16699267)

  • 1. Peripheral opioids for functional GI disease: a reappraisal.
    Lembo A
    Dig Dis; 2006; 24(1-2):91-8. PubMed ID: 16699267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of opioid-induced gut dysfunction.
    Holzer P
    Expert Opin Investig Drugs; 2007 Feb; 16(2):181-94. PubMed ID: 17243938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies.
    Kurz A; Sessler DI
    Drugs; 2003; 63(7):649-71. PubMed ID: 12656645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid-induced bowel dysfunction.
    Chang HY; Lembo AJ
    Curr Treat Options Gastroenterol; 2008 Feb; 11(1):11-8. PubMed ID: 21063859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The involvement of the mu-opioid receptor in gastrointestinal pathophysiology: therapeutic opportunities for antagonism at this receptor.
    DeHaven-Hudkins DL; DeHaven RN; Little PJ; Techner LM
    Pharmacol Ther; 2008 Jan; 117(1):162-87. PubMed ID: 18022696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of opioid ligands in the irritable bowel syndrome.
    Corazziari E
    Can J Gastroenterol; 1999 Mar; 13 Suppl A():71A-75A. PubMed ID: 10202212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripherally acting mu-opioid receptor antagonists and postoperative ileus: mechanisms of action and clinical applicability.
    Viscusi ER; Gan TJ; Leslie JB; Foss JF; Talon MD; Du W; Owens G
    Anesth Analg; 2009 Jun; 108(6):1811-22. PubMed ID: 19448206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opioid-induced bowel dysfunction.
    Thomas J
    J Pain Symptom Manage; 2008 Jan; 35(1):103-13. PubMed ID: 17981003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alvimopan, a selective peripherally acting mu-opioid antagonist.
    Camilleri M
    Neurogastroenterol Motil; 2005 Apr; 17(2):157-65. PubMed ID: 15787936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opioid-induced gastrointestinal dysfunction.
    Mehendale SR; Yuan CS
    Dig Dis; 2006; 24(1-2):105-12. PubMed ID: 16699269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drugs acting on serotonin receptors for the treatment of functional GI disorders.
    Tonini M; Pace F
    Dig Dis; 2006; 24(1-2):59-69. PubMed ID: 16699264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction--a 21-day treatment-randomized clinical trial.
    Paulson DM; Kennedy DT; Donovick RA; Carpenter RL; Cherubini M; Techner L; Du W; Ma Y; Schmidt WK; Wallin B; Jackson D
    J Pain; 2005 Mar; 6(3):184-92. PubMed ID: 15772912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel opioid antagonists for opioid-induced bowel dysfunction.
    Diego L; Atayee R; Helmons P; Hsiao G; von Gunten CF
    Expert Opin Investig Drugs; 2011 Aug; 20(8):1047-56. PubMed ID: 21663526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of drugs for gastrointestinal motor disorders: translating science to clinical need.
    Sanger GJ; Alpers DH
    Neurogastroenterol Motil; 2008 Mar; 20(3):177-84. PubMed ID: 18257767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alvimopan: a peripherally acting mu-opioid receptor antagonist.
    Leslie JB
    Drugs Today (Barc); 2007 Sep; 43(9):611-25. PubMed ID: 17940638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical studies of opioids and opioid antagonists on gastrointestinal function.
    Greenwood-Van Meerveld B; Gardner CJ; Little PJ; Hicks GA; Dehaven-Hudkins DL
    Neurogastroenterol Motil; 2004 Oct; 16 Suppl 2():46-53. PubMed ID: 15357851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, placebo-controlled phase 3 trial (Study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain.
    Irving G; Pénzes J; Ramjattan B; Cousins M; Rauck R; Spierings EL; Kleoudis CS; Snidow JW; Pierce A; Wurzelmann J; Mortensen ER
    J Pain; 2011 Feb; 12(2):175-84. PubMed ID: 21292168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basic and clinical pharmacology of new motility promoting agents.
    Galligan JJ; Vanner S
    Neurogastroenterol Motil; 2005 Oct; 17(5):643-53. PubMed ID: 16185302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New-generation 5-HT4 receptor agonists: potential for treatment of gastrointestinal motility disorders.
    Manabe N; Wong BS; Camilleri M
    Expert Opin Investig Drugs; 2010 Jun; 19(6):765-75. PubMed ID: 20408739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review article: the hypersensitive gut--peripheral kappa agonists as a new pharmacological approach.
    Junien JL; Riviere P
    Aliment Pharmacol Ther; 1995 Apr; 9(2):117-26. PubMed ID: 7605851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.